Production (Stage)
E
Kezar Life Sciences, Inc. KZR
$4.40 $0.020.46% NASDAQ
Recommendation
Prev Close
$4.40
Volume
18,699
Avg Vol (90D)
29,028
Market Cap
$32.15M
Dividend & Yield
--
52-Week Range
$3.62 - $9.18
P/E (TTM)
--
EPS (TTM)
-$13.55
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Analysts Anticipate 21% Gains Ahead For DFAT
5/29/2025 - ETF Channel
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
5/28/2025 - GuruFocus
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
5/28/2025 - Business Wire
Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?
5/27/2025 - Zacks Investment Research
Sphera Funds Management LTD. Lowers Stake in Kezar Life Sciences, Inc. (NASDAQ:KZR)
5/16/2025 - Ticker Report
Analysts Conflicted on These Healthcare Names: Kezar Life Sciences (KZR), Eli Lilly & Co (LLY) and Becton Dickinson (BDX)
5/15/2025 - TipRanks Financial Blog
Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
5/13/2025 - GuruFocus
Kezar Life Sciences reports Q1 EPS ($2.27), consensus ($2.65)
5/13/2025 - TipRanks Financial Blog
Kezar Life Sciences reports Q1 EPS ($2.27), consensus ($2.65)
5/13/2025 - The Fly
Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
5/13/2025 - Business Wire
ADAR1 Capital Management LLC Sells 1,190,869 Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR)
4/7/2025 - Ticker Report
Kezar Life Sciences price target lowered to $7 from $9 at Wells Fargo
3/26/2025 - TipRanks Financial Blog
Kezar Life Sciences price target lowered by $2 at Wells Fargo, here's why
3/26/2025 - The Fly
Analysts' Opinions Are Mixed on These Healthcare Stocks: Roche Holding AG (OtherRHHVF), Kezar Life Sciences (KZR) and Axsome Therapeutics (AXSM)
3/26/2025 - TipRanks Financial Blog
Kezar Life Sciences Reports Promising AIH Trial Results
3/26/2025 - TipRanks Financial Blog
Kezar Life Sciences, Inc. (KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call (Transcript)
3/25/2025 - Seeking Alpha: Transcripts
Kezar Life Sciences, Inc. (KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call (Transcript)
3/25/2025 - SeekingAlpha
Kezar Life Sciences reports topline results from PORTOLA trial
3/25/2025 - TipRanks Financial Blog
William Blair Sticks to Their Buy Rating for Kezar Life Sciences (KZR)
3/25/2025 - TipRanks Financial Blog
Kezar Life Sciences Touts Positive Data From Mid-Stage Study For Chronic Liver Disease Drug Candidate
3/25/2025 - Benzinga
Kezar Life Sciences reports topline results from PORTOLA trial
3/25/2025 - The Fly
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
3/25/2025 - Business Wire
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating ...
3/24/2025 - GuruFocus
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
3/24/2025 - Business Wire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$82.02M
EBIT (TTM)
-$83.05M
Net Income (TTM)
-$78.63M
Balance Sheet
Total Assets (Q)
$125.26M
Total Debt (Q)
$14.11M
Total Liabilities (Q)
$22.19M
Book Value Per Share (Q)
$14.11
Cash Flow
Cash from Operations (TTM)
-$68.54M
Cash from Investing (TTM)
$73.76M
Cash from Financing (TTM)
-$1.20M
Net Change in Cash (TTM)
$3.97M
Filings
Filing Date
Tuesday, May 13, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 11 and 15 (est)
Price History
Loading...
Beta
1.67
7-Day Total Return
5.52%
30-Day Total Return
-6.38%
60-Day Total Return
-24.53%
90-Day Total Return
-31.57%
Year to Date Total Return
-33.03%
1-Year Total Return
-35.74%
2-Year Total Return
-84.88%
3-Year Total Return
-91.91%
5-Year Total Return
-92.97%
52-week Low
Apr 04, 2025 - $3.62
52-week High
Oct 09, 2024 - $9.18
Valuation
Market Cap
$32.15M - Nano Cap
Enterprise Value
-$68.11M
Price/Sales (TTM)
--
Price/Book (Q)
0.31
Dividends and Shares
Shares Outstanding
7.31M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.kezarlifesciences.com
Phone Number
650 822 5600
Address
4000 Shoreline Court
South San Francisco, CA 94080
Country
United States
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases... more
NASDAQ 06/06/2025 4:00PM Eastern Quotes delayed